Loading…

Protective effects of lupeol in rats with renal ischemia‑reperfusion injury

Acute kidney injury (AKI) caused by ischemia and, exogenous or endogenous nephrotoxic agents poses a serious health issue. AKI is seen in 1% of all hospital admissions, 2-5% of hospitalizations and 67% of intensive care unit (ICE) patients. The in-hospital mortality rates for AKI is 40-50, and >5...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2024-08, Vol.28 (2), Article 313
Main Authors: Kapisiz, Alparslan, Kaya, Cem, Eryilmaz, Sibel, Karabulut, Ramazan, Turkyilmaz, Zafer, Inan, Mehmet Arda, Gulbahar, Ozlem, Sonmez, Kaan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c371t-f9a9caa41c08e0216c3c36c8eb5d4fa6a790a753ae1fe54b89deb9db7dc50dd33
container_end_page
container_issue 2
container_start_page
container_title Experimental and therapeutic medicine
container_volume 28
creator Kapisiz, Alparslan
Kaya, Cem
Eryilmaz, Sibel
Karabulut, Ramazan
Turkyilmaz, Zafer
Inan, Mehmet Arda
Gulbahar, Ozlem
Sonmez, Kaan
description Acute kidney injury (AKI) caused by ischemia and, exogenous or endogenous nephrotoxic agents poses a serious health issue. AKI is seen in 1% of all hospital admissions, 2-5% of hospitalizations and 67% of intensive care unit (ICE) patients. The in-hospital mortality rates for AKI is 40-50, and >50% for ICE patients. Ischemia-reperfusion (I/R) injury in the kidney can activate inflammatory responses and oxidative stress, resulting in AKI. The common endpoint in acute tubular necrosis is a cellular insult secondary to ischemia or direct toxins, which results in effacement of brush border, cell death and decreased function of tubular cells. The aim of the present study was to assess if the reported antioxidant and anti-inflammatory agent lupeol can exert any effects against renal I/R damage. In total, 24 Wistar Albino rats were randomly assigned into four groups of 6, namely Sham, lupeol, ischemia and therapy groups. In the lupeol group, intraperitoneal administration of 100 mg/kg lupeol was given 1 h before laparotomy, whilst only laparotomy was conducted in the sham group. The renal arteries of both kidneys were clamped for 45 min, 1 h after either intraperitoneal saline injection (in the ischemia group) or 100 mg/kg lupeol application (in the therapy group). The blood samples and renal tissues of all rats were collected after 24 h. In blood samples, blood urea nitrogen (BUN) was measured by the urease enzymatic method, and creatinine was measured by the kinetic Jaffe method. Using ELISA method, TNF-[alpha] and IL-6 levels were measured in the blood samples, whereas malondialdehyde (MDA), glutathione (GSH), caspase-3 levels were measured in kidney tissues. In addition, kidney histopathological analysis was performed by evaluating the degree of degeneration, tubular dilatation, interstitial lymphocyte infiltration, protein cylinders, necrosis and loss of brush borders. It was determined that renal damage occurred due to higher BUN, creatinine, MDA, TNF-[alpha] and caspase-3 values observed in the kidney tissues and blood samples of rats in ischemia group compared with the Sham group. Compared with those in the ischemia group, rats in the therapy group exhibited increased levels of GSH and reduced levels of BUN, TNF-[alpha], MDA. Furthermore, the ischemia group also had reduced histopathological damage scores. Although differences in creatinine, IL-6 and caspase-3 levels were not statistically significant, they were markedly reduced in the treatment group. Ta
doi_str_mv 10.3892/etm.2024.12602
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11190881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A806500517</galeid><sourcerecordid>A806500517</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-f9a9caa41c08e0216c3c36c8eb5d4fa6a790a753ae1fe54b89deb9db7dc50dd33</originalsourceid><addsrcrecordid>eNptUU1LLDEQDKKoqFfPA--8a_dkPpKTiOhTUPSg55DJdNwsM5M1mVG8vb_gX_SXGHV5Ipgc0lSqi-4qxg4R5lzI_IjGfp5DXswxryDfYLtYy3yGgOXmugYpcIcdxLiEdMoKhSi32U7qRoRC7LLr2-BHMqN7ooysTVXMvM26aUW-y9yQBZ2QZzcuskCDTlA0C-qdfvv3GmhFwU7R-SExl1N42WdbVneRDtbvHrs_P7s7vZhd3fy9PD25mhle4zizUkujdYEGBEGOleGGV0ZQU7aF1ZWuJei65JrQUlk0QrbUyLapW1NC23K-x46_dFdT01NraBiD7tQquF6HF-W1Uz9_BrdQD_5JIaIEITAp_FkrBP84URzV0k8hLRgVB1FUuagAvlkPuiPlBuuTmumTB-pEQFUmS7FOrPkvrHTbZJTxA1mX8N8aTPAxBrL_J0dQH8mqlKz6SFZ9JsvfAVzVlts</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3084628600</pqid></control><display><type>article</type><title>Protective effects of lupeol in rats with renal ischemia‑reperfusion injury</title><source>PubMed Central Free</source><creator>Kapisiz, Alparslan ; Kaya, Cem ; Eryilmaz, Sibel ; Karabulut, Ramazan ; Turkyilmaz, Zafer ; Inan, Mehmet Arda ; Gulbahar, Ozlem ; Sonmez, Kaan</creator><creatorcontrib>Kapisiz, Alparslan ; Kaya, Cem ; Eryilmaz, Sibel ; Karabulut, Ramazan ; Turkyilmaz, Zafer ; Inan, Mehmet Arda ; Gulbahar, Ozlem ; Sonmez, Kaan</creatorcontrib><description>Acute kidney injury (AKI) caused by ischemia and, exogenous or endogenous nephrotoxic agents poses a serious health issue. AKI is seen in 1% of all hospital admissions, 2-5% of hospitalizations and 67% of intensive care unit (ICE) patients. The in-hospital mortality rates for AKI is 40-50, and &gt;50% for ICE patients. Ischemia-reperfusion (I/R) injury in the kidney can activate inflammatory responses and oxidative stress, resulting in AKI. The common endpoint in acute tubular necrosis is a cellular insult secondary to ischemia or direct toxins, which results in effacement of brush border, cell death and decreased function of tubular cells. The aim of the present study was to assess if the reported antioxidant and anti-inflammatory agent lupeol can exert any effects against renal I/R damage. In total, 24 Wistar Albino rats were randomly assigned into four groups of 6, namely Sham, lupeol, ischemia and therapy groups. In the lupeol group, intraperitoneal administration of 100 mg/kg lupeol was given 1 h before laparotomy, whilst only laparotomy was conducted in the sham group. The renal arteries of both kidneys were clamped for 45 min, 1 h after either intraperitoneal saline injection (in the ischemia group) or 100 mg/kg lupeol application (in the therapy group). The blood samples and renal tissues of all rats were collected after 24 h. In blood samples, blood urea nitrogen (BUN) was measured by the urease enzymatic method, and creatinine was measured by the kinetic Jaffe method. Using ELISA method, TNF-[alpha] and IL-6 levels were measured in the blood samples, whereas malondialdehyde (MDA), glutathione (GSH), caspase-3 levels were measured in kidney tissues. In addition, kidney histopathological analysis was performed by evaluating the degree of degeneration, tubular dilatation, interstitial lymphocyte infiltration, protein cylinders, necrosis and loss of brush borders. It was determined that renal damage occurred due to higher BUN, creatinine, MDA, TNF-[alpha] and caspase-3 values observed in the kidney tissues and blood samples of rats in ischemia group compared with the Sham group. Compared with those in the ischemia group, rats in the therapy group exhibited increased levels of GSH and reduced levels of BUN, TNF-[alpha], MDA. Furthermore, the ischemia group also had reduced histopathological damage scores. Although differences in creatinine, IL-6 and caspase-3 levels were not statistically significant, they were markedly reduced in the treatment group. Taken together, these findings suggest that lupeol can prevent kidney damage as mainly evidenced by the reduced histopathological damage scores, decreased levels of oxidative stress and reduced levels of inflammatory markers. These properties may allow lupeol to be used in the treatment of AKI. Key words: lupeol, renal, ischemia/reperfusion injury, experimental study</description><identifier>ISSN: 1792-0981</identifier><identifier>EISSN: 1792-1015</identifier><identifier>DOI: 10.3892/etm.2024.12602</identifier><identifier>PMID: 38911048</identifier><language>eng</language><publisher>Athens: Spandidos Publications</publisher><subject>Abdomen ; Acute renal failure ; Analysis ; Animals ; Antioxidants ; Apoptosis ; Cancer therapies ; Care and treatment ; Complications and side effects ; Creatinine ; Diagnosis ; Health aspects ; Ischemia ; Ketamine ; Kidney function tests ; Kidneys ; Kinases ; Laparotomy ; Risk factors ; Toxicity ; Veins &amp; arteries</subject><ispartof>Experimental and therapeutic medicine, 2024-08, Vol.28 (2), Article 313</ispartof><rights>COPYRIGHT 2024 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2024</rights><rights>Copyright: © 2024 Kapisiz et al. 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c371t-f9a9caa41c08e0216c3c36c8eb5d4fa6a790a753ae1fe54b89deb9db7dc50dd33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11190881/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11190881/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Kapisiz, Alparslan</creatorcontrib><creatorcontrib>Kaya, Cem</creatorcontrib><creatorcontrib>Eryilmaz, Sibel</creatorcontrib><creatorcontrib>Karabulut, Ramazan</creatorcontrib><creatorcontrib>Turkyilmaz, Zafer</creatorcontrib><creatorcontrib>Inan, Mehmet Arda</creatorcontrib><creatorcontrib>Gulbahar, Ozlem</creatorcontrib><creatorcontrib>Sonmez, Kaan</creatorcontrib><title>Protective effects of lupeol in rats with renal ischemia‑reperfusion injury</title><title>Experimental and therapeutic medicine</title><description>Acute kidney injury (AKI) caused by ischemia and, exogenous or endogenous nephrotoxic agents poses a serious health issue. AKI is seen in 1% of all hospital admissions, 2-5% of hospitalizations and 67% of intensive care unit (ICE) patients. The in-hospital mortality rates for AKI is 40-50, and &gt;50% for ICE patients. Ischemia-reperfusion (I/R) injury in the kidney can activate inflammatory responses and oxidative stress, resulting in AKI. The common endpoint in acute tubular necrosis is a cellular insult secondary to ischemia or direct toxins, which results in effacement of brush border, cell death and decreased function of tubular cells. The aim of the present study was to assess if the reported antioxidant and anti-inflammatory agent lupeol can exert any effects against renal I/R damage. In total, 24 Wistar Albino rats were randomly assigned into four groups of 6, namely Sham, lupeol, ischemia and therapy groups. In the lupeol group, intraperitoneal administration of 100 mg/kg lupeol was given 1 h before laparotomy, whilst only laparotomy was conducted in the sham group. The renal arteries of both kidneys were clamped for 45 min, 1 h after either intraperitoneal saline injection (in the ischemia group) or 100 mg/kg lupeol application (in the therapy group). The blood samples and renal tissues of all rats were collected after 24 h. In blood samples, blood urea nitrogen (BUN) was measured by the urease enzymatic method, and creatinine was measured by the kinetic Jaffe method. Using ELISA method, TNF-[alpha] and IL-6 levels were measured in the blood samples, whereas malondialdehyde (MDA), glutathione (GSH), caspase-3 levels were measured in kidney tissues. In addition, kidney histopathological analysis was performed by evaluating the degree of degeneration, tubular dilatation, interstitial lymphocyte infiltration, protein cylinders, necrosis and loss of brush borders. It was determined that renal damage occurred due to higher BUN, creatinine, MDA, TNF-[alpha] and caspase-3 values observed in the kidney tissues and blood samples of rats in ischemia group compared with the Sham group. Compared with those in the ischemia group, rats in the therapy group exhibited increased levels of GSH and reduced levels of BUN, TNF-[alpha], MDA. Furthermore, the ischemia group also had reduced histopathological damage scores. Although differences in creatinine, IL-6 and caspase-3 levels were not statistically significant, they were markedly reduced in the treatment group. Taken together, these findings suggest that lupeol can prevent kidney damage as mainly evidenced by the reduced histopathological damage scores, decreased levels of oxidative stress and reduced levels of inflammatory markers. These properties may allow lupeol to be used in the treatment of AKI. Key words: lupeol, renal, ischemia/reperfusion injury, experimental study</description><subject>Abdomen</subject><subject>Acute renal failure</subject><subject>Analysis</subject><subject>Animals</subject><subject>Antioxidants</subject><subject>Apoptosis</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Creatinine</subject><subject>Diagnosis</subject><subject>Health aspects</subject><subject>Ischemia</subject><subject>Ketamine</subject><subject>Kidney function tests</subject><subject>Kidneys</subject><subject>Kinases</subject><subject>Laparotomy</subject><subject>Risk factors</subject><subject>Toxicity</subject><subject>Veins &amp; arteries</subject><issn>1792-0981</issn><issn>1792-1015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNptUU1LLDEQDKKoqFfPA--8a_dkPpKTiOhTUPSg55DJdNwsM5M1mVG8vb_gX_SXGHV5Ipgc0lSqi-4qxg4R5lzI_IjGfp5DXswxryDfYLtYy3yGgOXmugYpcIcdxLiEdMoKhSi32U7qRoRC7LLr2-BHMqN7ooysTVXMvM26aUW-y9yQBZ2QZzcuskCDTlA0C-qdfvv3GmhFwU7R-SExl1N42WdbVneRDtbvHrs_P7s7vZhd3fy9PD25mhle4zizUkujdYEGBEGOleGGV0ZQU7aF1ZWuJei65JrQUlk0QrbUyLapW1NC23K-x46_dFdT01NraBiD7tQquF6HF-W1Uz9_BrdQD_5JIaIEITAp_FkrBP84URzV0k8hLRgVB1FUuagAvlkPuiPlBuuTmumTB-pEQFUmS7FOrPkvrHTbZJTxA1mX8N8aTPAxBrL_J0dQH8mqlKz6SFZ9JsvfAVzVlts</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Kapisiz, Alparslan</creator><creator>Kaya, Cem</creator><creator>Eryilmaz, Sibel</creator><creator>Karabulut, Ramazan</creator><creator>Turkyilmaz, Zafer</creator><creator>Inan, Mehmet Arda</creator><creator>Gulbahar, Ozlem</creator><creator>Sonmez, Kaan</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20240801</creationdate><title>Protective effects of lupeol in rats with renal ischemia‑reperfusion injury</title><author>Kapisiz, Alparslan ; Kaya, Cem ; Eryilmaz, Sibel ; Karabulut, Ramazan ; Turkyilmaz, Zafer ; Inan, Mehmet Arda ; Gulbahar, Ozlem ; Sonmez, Kaan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-f9a9caa41c08e0216c3c36c8eb5d4fa6a790a753ae1fe54b89deb9db7dc50dd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Abdomen</topic><topic>Acute renal failure</topic><topic>Analysis</topic><topic>Animals</topic><topic>Antioxidants</topic><topic>Apoptosis</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Creatinine</topic><topic>Diagnosis</topic><topic>Health aspects</topic><topic>Ischemia</topic><topic>Ketamine</topic><topic>Kidney function tests</topic><topic>Kidneys</topic><topic>Kinases</topic><topic>Laparotomy</topic><topic>Risk factors</topic><topic>Toxicity</topic><topic>Veins &amp; arteries</topic><toplevel>online_resources</toplevel><creatorcontrib>Kapisiz, Alparslan</creatorcontrib><creatorcontrib>Kaya, Cem</creatorcontrib><creatorcontrib>Eryilmaz, Sibel</creatorcontrib><creatorcontrib>Karabulut, Ramazan</creatorcontrib><creatorcontrib>Turkyilmaz, Zafer</creatorcontrib><creatorcontrib>Inan, Mehmet Arda</creatorcontrib><creatorcontrib>Gulbahar, Ozlem</creatorcontrib><creatorcontrib>Sonmez, Kaan</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection (ProQuest Medical &amp; Health Databases)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental and therapeutic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kapisiz, Alparslan</au><au>Kaya, Cem</au><au>Eryilmaz, Sibel</au><au>Karabulut, Ramazan</au><au>Turkyilmaz, Zafer</au><au>Inan, Mehmet Arda</au><au>Gulbahar, Ozlem</au><au>Sonmez, Kaan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective effects of lupeol in rats with renal ischemia‑reperfusion injury</atitle><jtitle>Experimental and therapeutic medicine</jtitle><date>2024-08-01</date><risdate>2024</risdate><volume>28</volume><issue>2</issue><artnum>313</artnum><issn>1792-0981</issn><eissn>1792-1015</eissn><abstract>Acute kidney injury (AKI) caused by ischemia and, exogenous or endogenous nephrotoxic agents poses a serious health issue. AKI is seen in 1% of all hospital admissions, 2-5% of hospitalizations and 67% of intensive care unit (ICE) patients. The in-hospital mortality rates for AKI is 40-50, and &gt;50% for ICE patients. Ischemia-reperfusion (I/R) injury in the kidney can activate inflammatory responses and oxidative stress, resulting in AKI. The common endpoint in acute tubular necrosis is a cellular insult secondary to ischemia or direct toxins, which results in effacement of brush border, cell death and decreased function of tubular cells. The aim of the present study was to assess if the reported antioxidant and anti-inflammatory agent lupeol can exert any effects against renal I/R damage. In total, 24 Wistar Albino rats were randomly assigned into four groups of 6, namely Sham, lupeol, ischemia and therapy groups. In the lupeol group, intraperitoneal administration of 100 mg/kg lupeol was given 1 h before laparotomy, whilst only laparotomy was conducted in the sham group. The renal arteries of both kidneys were clamped for 45 min, 1 h after either intraperitoneal saline injection (in the ischemia group) or 100 mg/kg lupeol application (in the therapy group). The blood samples and renal tissues of all rats were collected after 24 h. In blood samples, blood urea nitrogen (BUN) was measured by the urease enzymatic method, and creatinine was measured by the kinetic Jaffe method. Using ELISA method, TNF-[alpha] and IL-6 levels were measured in the blood samples, whereas malondialdehyde (MDA), glutathione (GSH), caspase-3 levels were measured in kidney tissues. In addition, kidney histopathological analysis was performed by evaluating the degree of degeneration, tubular dilatation, interstitial lymphocyte infiltration, protein cylinders, necrosis and loss of brush borders. It was determined that renal damage occurred due to higher BUN, creatinine, MDA, TNF-[alpha] and caspase-3 values observed in the kidney tissues and blood samples of rats in ischemia group compared with the Sham group. Compared with those in the ischemia group, rats in the therapy group exhibited increased levels of GSH and reduced levels of BUN, TNF-[alpha], MDA. Furthermore, the ischemia group also had reduced histopathological damage scores. Although differences in creatinine, IL-6 and caspase-3 levels were not statistically significant, they were markedly reduced in the treatment group. Taken together, these findings suggest that lupeol can prevent kidney damage as mainly evidenced by the reduced histopathological damage scores, decreased levels of oxidative stress and reduced levels of inflammatory markers. These properties may allow lupeol to be used in the treatment of AKI. Key words: lupeol, renal, ischemia/reperfusion injury, experimental study</abstract><cop>Athens</cop><pub>Spandidos Publications</pub><pmid>38911048</pmid><doi>10.3892/etm.2024.12602</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-0981
ispartof Experimental and therapeutic medicine, 2024-08, Vol.28 (2), Article 313
issn 1792-0981
1792-1015
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11190881
source PubMed Central Free
subjects Abdomen
Acute renal failure
Analysis
Animals
Antioxidants
Apoptosis
Cancer therapies
Care and treatment
Complications and side effects
Creatinine
Diagnosis
Health aspects
Ischemia
Ketamine
Kidney function tests
Kidneys
Kinases
Laparotomy
Risk factors
Toxicity
Veins & arteries
title Protective effects of lupeol in rats with renal ischemia‑reperfusion injury
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A28%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20effects%20of%20lupeol%20in%20rats%20with%20renal%20ischemia%E2%80%91reperfusion%20injury&rft.jtitle=Experimental%20and%20therapeutic%20medicine&rft.au=Kapisiz,%20Alparslan&rft.date=2024-08-01&rft.volume=28&rft.issue=2&rft.artnum=313&rft.issn=1792-0981&rft.eissn=1792-1015&rft_id=info:doi/10.3892/etm.2024.12602&rft_dat=%3Cgale_pubme%3EA806500517%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c371t-f9a9caa41c08e0216c3c36c8eb5d4fa6a790a753ae1fe54b89deb9db7dc50dd33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3084628600&rft_id=info:pmid/38911048&rft_galeid=A806500517&rfr_iscdi=true